Evidence map›Paper›PMID 35278124›Full record

ArticlePsychopharmacology2022

Differential effects of the translocator protein 18 kDa (TSPO) ligand etifoxine and the benzodiazepine alprazolam on startle response to predictable threat in a NPU-threat task after acute and short-term treatment.

Lisa-Marie Brunner, Franziska Maurer, Kevin Weber, Johannes Weigl, Vladimir M Milenkovic, Rainer Rupprecht, Caroline Nothdurfter, Andreas Mühlberger

Abstract read
In one paragraph

Article in Psychopharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Lisa-Marie BrunnerDepartment of Medicine, Psychiatry and Psychotherapy, University Regensburg, 93053, Regensburg, Germany. lisa-marie.brunner@medbo.de.ORCID http://orcid.org/0000-0002-7555-1443
Franziska MaurerDepartment of Medicine, Psychiatry and Psychotherapy, University Regensburg, 93053, Regensburg, Germany.
Kevin WeberDepartment of Medicine, Psychiatry and Psychotherapy, University Regensburg, 93053, Regensburg, Germany.
Johannes WeiglDepartment of Medicine, Psychiatry and Psychotherapy, University Regensburg, 93053, Regensburg, Germany.
Vladimir M MilenkovicDepartment of Medicine, Psychiatry and Psychotherapy, University Regensburg, 93053, Regensburg, Germany.
Rainer RupprechtDepartment of Medicine, Psychiatry and Psychotherapy, University Regensburg, 93053, Regensburg, Germany.
Caroline NothdurfterDepartment of Medicine, Psychiatry and Psychotherapy, University Regensburg, 93053, Regensburg, Germany.
Andreas MühlbergerDepartment of Psychology, Clinical Psychology and Psychotherapy, University Regensburg, Regensburg, Germany.

Funding

deutsche forschungsgemeinschaft GRK 2174/1 - 2017
6 · The paper itself

Abstract

rationaleBenzodiazepines have been extensively investigated in experimental settings especially after single administration, which mostly revealed effects on unpredictable threat (U-threat) rather than predictable threat (P-threat). Given the need for pharmacological alternatives with a preferable side-effect profile and to better represent clinical conditions, research should cover also other anxiolytics and longer application times.

objectivesThe present study compared the acute and short-term effects of the translocator protein 18 kDa (TSPO) ligand etifoxine and the benzodiazepine alprazolam on P-threat and U-threat while controlling for sedation.

methodsSixty healthy male volunteers, aged between 18 and 55 years, were randomly assigned to receive a daily dose of either 150 mg etifoxine, 1.5 mg alprazolam, or placebo for 5 days. On days 1 and 5 of intake, they performed a NPU-threat task including neutral (N), predictable (P), and unpredictable (U) conditions, while startle responsivity and self-reports were studied. Sedative effects were assessed using a continuous performance test.

resultsNeither alprazolam nor etifoxine affected startle responsivity to U-threat on any of the testing days. While etifoxine reduced the startle response to P-threat on day 1 of treatment for transformed data, a contrary effect of alprazolam was found for raw values. No effects on self-reports and no evidence of sedation could be observed for either drug.

conclusionsNone of the anxiolytic substances had an impact on startle potentiation to U-threat even after several days of intake. The effects of the anxiolytics on startle responsivity to P-threat as well as implications for future studies are discussed.

Indexed as

AlprazolamAnti-Anxiety AgentsAdolescentAdultBenzodiazepinesHumansLigandsMaleMiddle AgedOxazinesReceptors, GABAReflex, StartleYoung AdultAlprazolamAnti-Anxiety AgentsBenzodiazepinesetifoxineLigandsOxazinesReceptors, GABATSPO protein, humanAlprazolamEtifoxineGABAA receptorNPU-threat taskPredictable threatTranslocator protein 18 kDa (TSPO)Unpredictable threat

Identifiers

PMID35278124
PMCPMC9205810

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.